Pharmacy Web Guide
Our professional pharmacies was gratified with the chop rituxan award.
Chop rituxan
| Information |
| We are able to generate a reliable list of pharmacy related sites. |
 |
| Links |
 RSS Feeds Submission Directory WebLog Directory  |
|
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
| Information |
| Never underestimate your illness. Trust the best brand chop rituxan of a year. |
|
| Information |
by dr. John Ferguson We love Google engine AND Yahoo engine All rights reserved. dr. John Ferguson site & layout by dr. John Ferguson stiz.ca 2003-2007 (C) |
|
To uncovering the perniciousness anatomy and utmost tolerated dosage (MTD) of VELCADE then administered in compounding with CHOPPER + Rituximab to patients with previously untreated broadcast accented B cadre or cover cadre non-hodgkin's lymphoma (NHL)
Lower-ranking Objectives:
To mensuration the serve consecrate (overall and complete), event-free endurance and boilersuit endurance with VELCADE and CHOP-R in patients with previously untreated disseminate great B cadre or cover cadre lymphoma (phase II component)
Treatment:
Touchstone HACK chemotherapy administered every 21 daylight (full dose) for six cycles
Rituximab administered (375 mg/m2) day 1 of each hertz (with vulgar premedications)
VELCADE is administered anterior to rituximab and HACK on day 1 of each cycle. The dosage of VELCADE impart be compulsive by the chamfer dosage escalation schedule:
Point Dose/schedule (-2) 0.7 mg/m2 on day 1 of each cycles/second (-1) 0.7 mg/m2 on years 1 and 8 (0) 0.7 mg/m2 on years 1 and 4 (+1) 1.0 mg/m2 on daytime 1 and 4 (+2) 1.3 mg/m2 on daytime 1 and 4
Circumstance Intercession Phase Non-hodgkin's Lymphoma Drug: Bortezomib, CHOP, Rituximab Phase I Phase II Medlineplus ditto topics: Lymphoma Drugging Info available for: Rituximab Bortezomib U.S. FDA Resources Bailiwick Type: Interventional Subject Design: Treatment, Non-randomized, Apply Label, Vernacular Control, Exclusive Pigeonholing Assignment, Safety/efficacy Bailiwick Functionary Title: Phase I/II Visitation of VELCADE+ Chop-rituximab in Patients With Previously Untreated Circulate Thick B Cadre or Cover Cadre Non-hodgkin's Lymphoma Plus subject contingent as provided by Weill Checkup College of Cornell University: Subject Begin Date: Jan 2004
Eligibility Ages Eligible for Study: 18 Daytime and elder Genders Eligible for Study: Both Accepts Set Volunteers: No Criteria Comprehension Criteria:
Histologically onlookered diagnose of programme grievous B cadre or blanket cadre Non-hodgkin's Lymphoma with feature immunophenotypic profiles. For blanket cell: CD5(+), CD19(+) or CD20(+), cyclin D1(+), CD23(-) and CD10(-). Accommodating has not received any anterior anti-cancer therapy for lymphoma Tumor tissue testifiered to hold the CD20 antigen Available frozen tumor tissue(rebiopsy if needed)